Volume 7.03 | Jan 26

Pancreatic Cell News 7.03 January 26, 2016
Pancreatic Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PACN on Twitter
No More Insulin Injections? Encapsulated Pancreatic Cells Offer Possible New Diabetes Treatment.
Researchers have designed a material that can be used to encapsulate human islet cells before transplanting them. In tests on mice, they showed that these encapsulated human cells could cure diabetes for up to six months, without provoking an immune response. [Press release from Massachusetts Institute of Technology discussing online prepublication in Nature Medicine] Press Release | Abstract
Weekend-Free Culture hPSCs with mTeSR™1 or TeSR™-E8™
PUBLICATIONS (Ranked by impact factor of the journal)

SerpinB1 Promotes Pancreatic β Cell Proliferation
Using proteomics the authors showed that serpinB1, a protease inhibitor, which is abundant in the hepatocyte secretome and sera derived from liver insulin receptor knockout mice, is the liver-derived secretory protein that regulates β cell proliferation in humans, mice, and zebrafish. [Cell Metab] Abstract | Graphical Abstract

Inhibition of hIAPP Amyloid Aggregation and Pancreatic β-Cell Toxicity by OH-Terminated PAMAM Dendrimer
Scientists showed that generation-3 OH-terminated poly(amidoamine) dendrimer, a polymeric nanoparticle, can effectively halt the aggregation of human islet amyloid polypeptide (hIAPP, or amylin) and shut down hIAPP toxicity in pancreatic MIN6 and NIT-1 cells as well as in mouse islets. [Small] Abstract

Inhibition of the MAP3 Kinase Tpl2 Protects Rodent and Human β-Cells from Apoptosis and Dysfunction Induced by Cytokines and Enhances Anti-Inflammatory Actions of Exendin-4
Scientists demonstrated that tumor progression locus 2 (Tpl2) is expressed in INS-1E β-cells, mouse and human islets, is activated and upregulated by cytokines and mediates ERK1/2, JNK and p38 activation. Tpl2 inhibition protects β-cells, mouse and human islets from cytokine-induced apoptosis and preserves glucose-induced insulin secretion in mouse and human islets exposed to cytokines. [Cell Death Dis] Full Article


Functional Annotation of Rare Gene Aberration Drivers of Pancreatic Cancer
Investigators describe a platform enabling functionalization of rare gene mutations through their high-throughput construction, molecular barcoding and delivery to cancer models for in vivo tumor driver screens. They apply these technologies to identify oncogenic drivers of pancreatic ductal adenocarcinoma. [Nat Commun] Full Article

A Novel Association of Neuropilin-1 and MUC1 in Pancreatic Ductal Adenocarcinoma: Role in Induction of VEGF Signaling and Angiogenesis
Expression of tumor-associated MUC1 (tMUC1) positively correlated with neuropilin-1 levels in human and mouse pancreatic ductal adenocarcinoma (PDA). Further, tMUC1hi PDA cells secreted high levels of vascular endothelial growth factor (VEGF) and expressed high levels of VEGF receptor 2 (VEGFR2) and its phosphorylated forms as compared with tMUC1low/null PDA. [Oncogene] Abstract

Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities
CDK4/6 inhibition stimulated glycolytic and oxidative metabolism and was associated with an increase in mTORC1 activity. MTOR and MEK inhibitors potently cooperate with CDK4/6 inhibition in eliciting cell-cycle exit. However, MTOR inhibition fully suppressed metabolism and yielded apoptosis and suppression of tumor growth in xenograft models. [Cell Rep] Full Article | Graphical Abstract | Press Release

β2-Adrenergic Receptor Signaling Promotes Pancreatic Ductal Adenocarcinoma (PDAC) Progression through Activating PCBP2-dependent C-myc Expression
Researchers identified poly(rC)-binding protein 2 (PCBP2) as a novel binding partner for β2-adrenergic receptor (β2-AR) using immunoprecipitation-mass spectrometry (IP-MS) approach. The association between β2-AR and PCBP2 was verified using reciprocal immunoprecipitation. Additionally, they found significant interaction and co-localization of the two proteins in the presence of β2-AR agonist in Panc-1 and Bxpc3 pancreatic ductal adenocarcinoma cells. [Cancer Lett] Abstract

Nimbolide Inhibits Pancreatic Cancer Growth and Metastasis through ROS-Mediated Apoptosis and Inhibition of Epithelial-to-Mesenchymal Transition
Scientists assessed the anticancer properties of nimbolide against pancreatic cancer. Data reveal that nimbolide induces excessive generation of reactive oxygen species (ROS), thereby regulating both apoptosis and autophagy in pancreatic cancer cells. [Sci Rep] Full Article

Take the If out of Diff: Definitive Endoderm
Chromatin Regulators in Pancreas Development and Diabetes
The authors describe current research on chromatin regulators and their roles in pancreas development and the maintenance of mature β cell function, which, once elucidated, will help better understand how β cell differentiation occurs and is maintained. [Trends Endocrinol Metab] Abstract

Pancreatic Cancer: Current Research and Future Directions
The aim of this review is to describe the latest discoveries and advancements in pancreatic cancer research and to discuss future directions. [Biochim Biophys Acta] Abstract

Visit our reviews page to see a complete list of reviews in the pancreatic cell research field.
NewLink Genetics Presents Phase Ib Data of Indoximod in Combination with Gemcitabine/Nab-Paclitaxel for Patients with Metastatic Pancreatic Cancer that Show Encouraging Durable Responses with Delayed Pattern
NewLink Genetics Corporation including both cellular immunotherapy and checkpoint inhibitor platforms, announced the presentation of data that describes a combination therapy of indoximod, an IDO pathway inhibitor, plus gemcitabine/nab-paclitaxel, for patients with metastatic pancreatic cancer. [Press release from NewLink Genetics Corporation discussing research presented at the 2016 Gastrointestinal Cancers Symposium, San Francisco] Press Release

Phase I Trial Data for Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin (mFOLFIRINOX) in Metastatic Pancreatic Adenocarcinoma to Be Presented at the Annual Gastrointestinal Cancers Symposium
Cornerstone Pharmaceuticals, Inc., announced that data from the Phase I clinical trial evaluating CPI-613 in combination with modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) to treat metastatic pancreatic adenocarcinoma will be presented. [Press release from Cornerstone Pharmaceuticals, Inc discussing research presented at the Annual Gastrointestinal Cancers Symposium, San Francisco] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells?
Request your free wallchart.
PCRF Launches World’s First National Tissue Bank for Pancreatic Cancer Research
The Pancreatic Cancer Research Fund (PCRF) Tissue Bank brings together surgeons, pathologists, oncologists, researchers and database experts to co-ordinate a national – and ultimately international -­ resource that will help to develop new treatments and bring these to patients much faster. [The Pancreatic Cancer Research Fund] Press Release

C. Ronald Kahn, M.D., is Awarded the Prestigious Wolf Prize in Medicine for Groundbreaking Research in Insulin Signaling
The Wolf Foundation announced that it has awarded the Wolf Prize in Medicine to C. Ronald Kahn, M.D., Chief Academic Officer and Senior Investigator at Joslin Diabetes Center and the Mary K. Iacocca Professor of Medicine at Harvard Medical School. [Joslin Diabetes Center] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW The Stem Cell Niche 2016
May 22-26, 2016
Hillerod, Denmark

Visit our events page to see a complete list of events in the pancreatic cell community.
NEW Research Associate – Cancer Pharmacology in Pancreatic Adenocarcinoma (University of Cambridge)

Post-Doc Fellowship – Computational Analysis Pancreas (Karolinska Institutet)

Post-Doc Fellowship/PhD Studentship – Cancer Metastasis (The University of Helsinki)

Post-Doc Fellowship (The Leibniz Institute for Plasma Science and Technology)

Post-Doc Researcher – Drug Discovery in Cancer/Diabetes (D. E. Shaw Research)

Post-Doc Fellowship – Diabetes Research (Sanford Research/University of South Dakota)

Faculty Position – Biomedical Metabolomics & Metabolism (University of Ottawa)

Post-Doc Researcher – Pancreatic Cancer (The Walter and Eliza Hall Institute of Medical Research)

Visiting Scientist – Diabetes (Danish Diabetes Academy)

Post-Doc Researcher – Type 1 Diabetes (University of Turku)

Post-Doc Researcher – Functional Genomics of Obesity (Inserm)

MD/PhD Researcher – Biomedical Sciences (Hannover Medical School)

PhD Studentship – Cancer Biology (University of Salzburg)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Pancreatic Cell News: Archives | Events | Contact Us